Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 76, Issue 3, pp 547–553 | Cite as

A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer

  • Tomohiro NishinaEmail author
  • Takeshi Kato
  • Kentaro Yamazaki
  • Takayuki Yoshino
  • Yoshinori Miyata
  • Taito Esaki
  • Toshikazu Moriwaki
  • Narikazu Boku
  • Ichinosuke Hyodo
Original Article

Abstract

Purpose

Adding leucovorin to fluorouracil is known to improve response rate and overall survival in first-line chemotherapy for metastatic colorectal cancer (mCRC). The present multicenter phase II study evaluated the efficacy and safety of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA).

Methods

Patients with unresectable and untreated mCRC received S-1 (40–60 mg bid) plus leucovorin (25 mg bid) orally for 1 week, and oxaliplatin (85 mg/m2) and bevacizumab (5 mg/kg) intravenously on day 1, every 2 weeks. Efficacy endpoints, including the response rate (the primary endpoint) and progression-free survival, were assessed by an independent review committee.

Results

Of the 29 eligible patients, 25 patients (86 %) had a partial response [95 % confidence interval (CI) 68–96 %] and the remaining four patients showed stable disease with a trend toward tumor shrinkage. The median progression-free survival was 15 months (95 % CI 10–26 months). The median overall survival was not reached after a median follow-up time of 34 months. The 3-year survival rate was 54 %. Curative resections of metastatic lesions were performed in eight patients (28 %). Common grade 3 or 4 adverse events were neutropenia (20 %), hypertension (23 %), anorexia (20 %), fatigue (17 %), diarrhea (10 %), and peripheral sensory neuropathy (53 %).

Conclusions

The SOLA therapy showed excellent efficacy and tolerable toxicities except for peripheral sensory neuropathy in patients with mCRC. Since oxaliplatin-induced neuropathy can be alleviated by modifying its administration, SOLA is a promising candidate regimen to be compared with FOLFOX plus bevacizumab in a future phase III trial.

Clinical trial number

JapicCTI-090881.

Keywords

S-1 Leucovorin Oxaliplatin SOLA Colorectal cancer Bevacizumab 

Notes

Acknowledgments

We thank the patients; their families; all the investigators who participated in the study; all of the independent data monitoring committee members (Y. Maehara, K. Aiba, and A. Sato); Y. Sakata as a medical adviser; all of the independent review committee members (J. Tanaka, S. Hironaka, and T. Ushimi); T. Tanase, Taiho Pharmaceutical Co., Ltd for statistical analysis; and M. Hiramatsu, Taiho Pharmaceutical Co., Ltd for his support of this report. This study was funded by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan. Employees of Taiho Pharmaceutical Co., Ltd were involved in the study design and the data collection and analysis. They also provided writing assistance.

Compliance with ethical standards

Conflict of interest

T Nishina has received honoraria from Taiho Pharmaceutical (Taiho), Chugai Pharmaceutical (Chugai), and Yakult Honsha (Yakult) and has received research funding from Taiho. T. Kato has received research funding from Taiho. K. Yamazaki has received honoraria from Taiho, Chugai, and Yakult and has received research funding from Taiho. T. Yoshino has received honoraria from Chugai and has received research funding from Taiho. Y. Miyata has received research funding from Taiho. T. Esaki has received honoraria from Taiho, Chugai, and Yakult and has received research funding from Taiho. T. Moriwaki has received honoraria from Taiho and Chugai and has received research funding from Taiho. N. Boku has received honoraria from Taiho and Yakult and has received research funding from Taiho. I. Hyodo has received honoraria and research funding from Taiho, Chugai and Yakult.

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Supplementary material

280_2015_2825_MOESM1_ESM.docx (36 kb)
Supplementary material 1 (DOCX 35 kb)

References

  1. 1.
    Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39:2–15PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Ohtsu A, Baba H, Sakata Y et al (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83:141–145PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Shirao K, Ohtsu A, Takada H et al (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355–2361CrossRefPubMedGoogle Scholar
  4. 4.
    Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278–1286CrossRefPubMedGoogle Scholar
  5. 5.
    Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853–860CrossRefPubMedGoogle Scholar
  6. 6.
    Thirion P, Michiels S, Pignon JP et al (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22:3766–3775CrossRefPubMedGoogle Scholar
  7. 7.
    Koizumi W, Boku N, Yamaguchi K et al (2010) Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 21:766–771PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Xu R, Li J, Xu J et al (2013) Phase II study of S-1 plus leucovorin (1 week treatment regimen followed by 1 week rest period) in patients with untreated metastatic colorectal cancer in Japan and China: comparing results of each country and updating overall survival. J Clin Oncol 31 (suppl 4; abstr 528)Google Scholar
  9. 9.
    Yamazaki K, Kuwano H, Ojima H et al (2015) A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol 75:569–577CrossRefPubMedGoogle Scholar
  10. 10.
    Yamada Y, Tahara M, Miya T et al (2008) Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 98:1034–1038PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Doi T, Boku N, Kato K et al (2010) Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40:913–920PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMedGoogle Scholar
  13. 13.
    Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47CrossRefPubMedGoogle Scholar
  14. 14.
    Wong R, Cunningham D, Barbachano Y et al (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22:2042–2048CrossRefPubMedGoogle Scholar
  15. 15.
    Okines A, Puerto OD, Cunningham D et al (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033–1038PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Van Cutsem E, Köhne C-H, Láng I, et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019CrossRefPubMedGoogle Scholar
  17. 17.
    Sommeijer DW, Shi Q, Meyer JP et al (2013) Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. J Clin Oncol 31 (suppl; abstr 3520)Google Scholar
  18. 18.
    de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2937–2938Google Scholar
  19. 19.
    Grothey A, Deschler B, Kroening H et al (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + Oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129a (abstr 512)Google Scholar
  20. 20.
    Brienza S, Vignoud J, Itzakhi M et al (1995) Oxaliplatin (LOHP): Global safety in 682 patients (pts). Proc Am Soc Clin Oncol 14:209 (abstr 513)Google Scholar
  21. 21.
    Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24:394–400CrossRefPubMedGoogle Scholar
  22. 22.
    Chuah B, Goh BC, Lee SC et al (2011) Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102:478–483CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Tomohiro Nishina
    • 1
    Email author
  • Takeshi Kato
    • 2
  • Kentaro Yamazaki
    • 3
  • Takayuki Yoshino
    • 4
  • Yoshinori Miyata
    • 5
  • Taito Esaki
    • 6
  • Toshikazu Moriwaki
    • 7
  • Narikazu Boku
    • 8
  • Ichinosuke Hyodo
    • 7
  1. 1.Department of Gastrointestinal Medical OncologyNational Hospital Organization Shikoku Cancer CenterMatsuyamaJapan
  2. 2.Department of SurgeryKansai Rosai HospitalAmagasakiJapan
  3. 3.Division of Gastrointestinal Oncology and EndoscopyShizuoka Cancer CenterShunto-gun, ShizuokaJapan
  4. 4.Department of Gastroenterology and Gastrointestinal OncologyNational Cancer Center Hospital EastKashiwaJapan
  5. 5.Department of Medical OncologySaku Central HospitalSakuJapan
  6. 6.Department of Gastrointestinal and Medical OncologyNational Kyushu Cancer CenterFukuokaJapan
  7. 7.Division of Gastroenterology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  8. 8.Department of Clinical OncologySt. Marianna University School of MedicineKawasakiJapan

Personalised recommendations